TRAIL receptor upregulation and the implication of KRAS/BRAF mutations in human colon cancer tumors

International Journal of Cancer

Volumn 125, Issue 9, 2009, Pages 2127-2135

  Oikonomou, Eftychia ^a   Kosmidou, Vivian ^a   Katseli, Anastasia ^b   Kothonidis, Konstantinos ^b   Mourtzoukou, Despina ^b   Kontogeorgos, George ^b   Andera, Ladislav ^c   Zografos, Georgios ^b   Pintzas, Alexander ^a  

^a INSTITUTE OF BIOLOGY   (Greece)

^b G GENNIMATAS GENERAL HOSPITAL   (Greece)

^c INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

Author keywords

BRAFV600E; Colon cancer; DR5; KRASG12 13; TRAIL

Indexed keywords

B RAF KINASE; ONCOPROTEIN; PROTEI KRAS; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 4; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 5; UNCLASSIFIED DRUG; BRAF PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; RAS PROTEIN;

ADULT; AGED; ARTICLE; COLON CANCER; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; COLON TUMOR; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; MUTATION; PHYSIOLOGY;

ADULT; AGED; AGED, 80 AND OVER; COLONIC NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; UP-REGULATION;

EID: 70249144378     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24613     Document Type: Article

References (31)

1. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-767
2. Mongkolsapaya J, Grimes JM, Chen N, Xu XN, Stuart DI, Jones EY, Screaton GR. Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation. Nat Struct Biol 1999;6:1048-1053 (Pubitemid 29519600)
3. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-162
4. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-163 (Pubitemid 29068521)
5. Galligan L, Longley DB, McEwan M, Wilson TR, McLaughlin K, Johnston PG. Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP. Mol Cancer Ther 2005;4:2026-2036
6. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996;271:12687-12690 (Pubitemid 26175834)
7. Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J, Fox JA. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 2001;299:31-38 (Pubitemid 32905115)
8. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, Hillan K, Totpal K, DeForge L, Schow P, Hooley J, Sherwood S, et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001;7:383-385 (Pubitemid 32298514)
9. Oikonomou E, Kothonidis K, Taoufik E, Probert E, Zografos G, Nasioulas G, Andera L, Pintzas A. Newly established tumourigenic primary human colon cancer cell lines are sensitive to TRAILinduced apoptosis in vitro and in vivo. Br J Cancer 2007;97:73-84. (Pubitemid 47012093)
10. Marini P, Denzinger S, Schiller D, Kauder S, Welz S, Humphreys R, Daniel PT, Jendrossek V, Budach W, Belka C. Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGSETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene 2006;25:5145-5154 (Pubitemid 44285983)
11. Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, Schlossman R, Hideshima T, Anderson KC. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 2001;98:795-804.
12. Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK, Huang HJ. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res 2000;60:847-853 (Pubitemid 30129513)
13. Daniels RA, Turley H, Kimberley FC, Liu XS, Mongkolsapaya J, Ch'En P, Xu XN, Jin BQ, Pezzella F, Screaton GR. Expression of TRAIL and TRAIL receptors in normal and malignant tissues. Cell Res 2005;15:430-438 (Pubitemid 41642871)
14. Hague A, Hicks DJ, Hasan F, Smartt H, Cohen GM, Paraskeva C, MacFarlane M. Increased sensitivity to TRAIL-induced apoptosis occurs during the adenoma to carcinoma transition of colorectal carcinogenesis. Br J Cancer 2005;92:736-742 (Pubitemid 40460611)
15. Koornstra JJ, Kleibeuker JH, van Geelen CM, Rijcken FE, Hollema H, de Vries EG, de JS. Expression of TRAIL (TNF-related apoptosisinducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J Pathol 2003;200:327-335 (Pubitemid 36827307)
16. Strater J, Hinz U, Walczak H, Mechtersheimer G, Koretz K, Herfarth C, Moller P, Lehnert T. Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. Clin Cancer Res 2002;8:3734-3740 (Pubitemid 35424763)
17. Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 1998;161:2833-2840 (Pubitemid 28425704)
18. Leithauser F, Dhein J, Mechtersheimer G, Koretz K, Bruderlein S, Henne C, Schmidt A, Debatin KM, Krammer PH, Moller P. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 1993;69:415-429 (Pubitemid 23335841)
19. Moller P, Koretz K, Leithauser F, Bruderlein S, Henne C, Quentmeier A, Krammer PH. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int J Cancer 1994;57:371-377 (Pubitemid 24168612)
20. Drosopoulos KG, Roberts ML, Cermak L, Sasazuki T, Shirasawa S, Andera L, Pintzas A. Transformation by oncogenic RAS sensitizes human colon cells to TRAIL-induced apoptosis by up-regulating death receptor 4 and death receptor 5 through a MEK-dependent pathway. J Biol Chem 2005;280:22856-22867 (Pubitemid 40853193)
21. Spierings DC, de Vries EG, Vellenga E, van den Heuvel FA, Koornstra JJ, Wesseling J, Hollema H, de JS. Tissue distribution of the death ligand TRAIL and its receptors. J Histochem Cytochem 2004;52:821-831 (Pubitemid 38703137)
22. Di PR, Secchiero P, Rana R, Gibellini D, Visani G, Bemis K, Zamai L, Miscia S, Zauli G. Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factor-related apoptosis- inducing ligand (TRAIL)-mediated cytotoxicity by selective up-regulation of TRAIL-R1. Blood 2001;97:2596-2603
23. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, BottomleyW, Davis N, Dicks E, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417: 949-954 (Pubitemid 34716871)
24. Yuen ST, Davies H, Chan TL, Ho JW, Bignell GR, Cox C, Stephens P, Edkins S, Tsui WW, Chan AS, Futreal PA, Stratton MR, et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 2002;62:6451-6455 (Pubitemid 35364105)
25. Sheikh MS, Burns TF, Huang Y, Wu GS, Amundson S, Brooks KS, Fornace AJ, Jr, el-Deiry WS. p53-Dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor a. Cancer Res 1998; 58:1593-1598 (Pubitemid 28215076)
26. Duiker EW, Mom CH, de JS, Willemse PH, Gietema JA, van der Zee AG, de Vries EG. The clinical trail of TRAIL. Eur J Cancer 2006; 42:2233-2240
27. Zhang XD, Franco A, Myers K, Gray C, Nguyen T, Hersey P. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAILinduced apoptosis of melanoma. Cancer Res 1999;59:2747-2753 (Pubitemid 29269125)
28. van Geelen CM, Westra JL, de Vries EG, Boersma-van EW, Zwart N, Hollema H, Boezen HM, Mulder NH, Plukker JT, de JS, Kleibeuker JH, Koornstra JJ. Prognostic significance of tumor necrosis factorrelated apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients. J Clin Oncol 2006;24:4998-5004. (Pubitemid 46631402)
29. Wang S, El-Deiry WS. Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil. Cancer Res 2004;64:6666-6672 (Pubitemid 39297928)
30. Zhang XD, Franco AV, Nguyen T, Gray CP, Hersey P. Differential localization and regulation of death and decoy receptors for TNFrelated apoptosis-inducing ligand (TRAIL) in human melanoma cells. J Immunol 2000;164:3961-3970 (Pubitemid 30215048)
31. Takimoto R, El-Deiry WS. Wild-type p53 transactivates the KILLER/ DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 2000;19:1735-1743 (Pubitemid 30200979)